Abstract: Provided is a curcumin pharmaceutical preparation that is highly water soluble, can maintain the concentration of free curcumin in the blood sufficiently high by being administered parenterally, can effectively obtain a pharmacological action of curcumin, and is highly safe. A pharmaceutical composition for parenteral administration, including a water-soluble substance conjugate of curcumin as an active component.

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Abstract: The present disclosure relates to methods of reducing accelerated blood clearance of at least one pegylated therapeutic composition in a subject suffering from a disease and in need of treatment. The methods involve administering at least one high molecular weight polyethylene glycol composition to a subject suffering from a disease. The administration of at least one high molecular weight polyethylene glycol composition can also be used to increase the circulation half-life of at least one pegylated therapeutic composition as well as restore the pharmacokinetics of the pegylated therapeutic composition in a subject having a high titer of anti-polyethylene glycol antibodies.

Abstract: The present invention relates to a long-acting single-chain insulin analog, a conjugate thereof, and uses of the same. In addition, the present invention relates to a method for preparing a long-acting single-chain insulin analog and a conjugate thereof.

Abstract: Provided herein are oligonucleotides, peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.

Abstract: Provided are ligand-conjugates and methods for targeted receptor-mediated cellular uptake of an entity of interest of desired activity and function.

Abstract: The present disclosure relates to an antibody-drug conjugate in which a modified antibody comprising a motif having a specific structure at the end of the antibody is conjugated to a drug via a linker, and a composition comprising the same, and more particularly to a modified antibody-drug conjugate (mADC) comprising a modified antibody that has a significantly increased conjugation yield of drug due to a motif bound to the heavy chain or light chain C-terminus of the antibody, and to a composition comprising the same.

Abstract: Provided herein are methods and materials for making antibody-polypeptide conjugates.

Abstract: The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.

Abstract: The present invention relates to a gene delivery complex comprising: a biocompatible polymer backbone; and pegylated lactoferrin connected to the biocompatible polymer backbone by means of a covalent bond. The gene delivery complex is orally administered into an individual, can be absorbed in vivo by means of a lactoferrin receptor, and enables the in vivo delivery of a target gene and the expression thereof.

Abstract: Methods and systems for distinguishing an astrocytic human brain tumor from a non-astrocytic human brain tumor. In one embodiment, a method includes the steps of staining tumor tissue from a subject suspected of having a brain tumor with SR101 and visualizing the tissue stained with SR101 with a fluorescence imaging device to confirm an astrocytic or non-astrocytic tumor type. Advantageously, tumor tissue from a subject is stained ex vivo, and the staining and visualizing steps are performed intraoperatively so as to guide the surgeon and thereby minimize or eliminate the need for a subsequent surgery.

Abstract: Disclosed are compositions and methods relating to novel tumor targeting peptides.

Abstract: This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system.

Abstract: Compositions and methods for detection and diagnosis of breast cancer are disclosed. In particular, the invention relates to the use of B7-H3-targeted imaging agents for molecular imaging of breast cancer. Vascular expression of B7-H3 is selectively and significantly higher in breast cancer tissues. Detection of B7-H3 can be used to distinguish between benign and malignant lesions with high diagnostic accuracy. B7-H3-targeted imaging agents can be produced by conjugation of a B7-H3-binding antibody, aptamer, or other ligand to various diagnostic agents, such as contrast agents, photoactive agents, or detectable labels that are useful for detection and medical imaging of breast cancer tumors.

Abstract: The present disclosure provides imaging agents that are useful for the detection and evaluation of heart conditions, such as myocardial infarction. Upon activation, the imaging agents of the present disclosure may be detected using an ultrasound imaging device.

Abstract: A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.

Abstract: Described herein generally are sterilization devices that can allow sterilization of surface(s) of instrument(s). Methods of using these devices are also described.

Abstract: Systems, apparatus, and methods are described for a disinfecting system formed of a plurality of modular units, wherein each modular unit is (1) coupleable to at least one other modular unit from the plurality of modular units and (2) includes an energy source from a plurality of energy sources. The plurality of energy sources can be configured to provide energy having an intensity capable of disinfecting a surface of the object located in a disinfecting area.

Abstract: A treatment method is capable of degrading or sterilizing harmful substances or microorganisms of which the degradation, detoxification, or the like is not easy for ozone gas alone. A harmful substance treatment method is one that makes ozone gas act on harmful substances, microorganisms, or the like in an environment humidified using a surfactant solution. The harmful substances include anticancer drugs. As a surfactant to be used, a non-ionic surfactant, an anionic surfactant, a cationic surfactant, or an amphoteric surfactant can be used.

Abstract: A system of generating an aerosol, by: (a) placing a liquid into a liquid chamber in an ultrasonic nebulization system having a cylindrical aerosol production chamber received within a cylindrical master chamber, and having top and bottom ultrasonic transducers; (b) passing air up through the aerosol production chamber; and (c) producing acoustic standing waves above the surface of the liquid with the top and bottom ultrasonic transducers, thereby generating an aerosol of the liquid by action of the standing waves.

Abstract: A system and method of disinfecting an area using germicidal radiation. The system is configured to capture images of an environment, analyze the images to determine locations of a person or unprotected skin of a person in the environment, and control one or more germicidal radiation emitters to decontaminate the environment where the person or exposed skin of persons in the environment are not located. The system and method allow for safe decontamination of an environment using hazardous levels of germicidal radiation while occupied by a person who may not be fully protected from the radiation.

Abstract: A method of using a sterilization wrap system including a permeable material having barrier properties and having a first surface and a second opposing surface, the exterior panel being substantially opaque or having a first level of translucence, and an interior panel including a permeable material having barrier properties and having a first surface and a second opposing surface, the interior panel having a level of translucence that is higher than the translucence of the exterior panel, the panels being joined together over at least a portion of their surfaces. Also disclosed is inspection of the sterilization wrap system for exterior panel breaches by looking for light passing through a panel facing the viewer.

Abstract: A process challenge device and method for evaluating and removal processes inside of narrow and hollow channels comprising sample, capsule having an inlet connector, a flow shaping element and an internal cavity, a lock—or end cap—for each capsule securing the sample inside the cavity. The tag being located in the capsule against one of the walls of the internal cavity that is shaped not to change the parameters of the fluid flow while it flows into said cavity and over the face of the sample simulating the flow through an equivalent narrow channel. Methods characterised by said process challenge device being loaded with a matching sample containing contamination for evaluation of effectiveness of a cleaning processes or blank sample for evaluation of contamination formation processes on said sample.

Abstract: An essential oil reflux-type atomizer comprising the following structures: a chassis, housing, atomization chamber, gas pump, gas tube, gas nozzle, oil nozzle, and filter atomization mechanism. Oil and gas flow together at the gas and oil nozzles to disperse and atomize the oil in the gas flow. A heater is used to raise the temperature of the oil where it is atomized, either by heating the oil itself or by heating the gas flowing into the oil. Thus, the atomizer can have improved performance, especially with essential oils having high viscosity and molecular weight.

Abstract: Apparatus for delivering a volatile material including a reservoir with an opening for containing a volatile material. A first membrane is disposed adjacent the opening of the reservoir, and a second membrane disposed adjacent the opening such that the first membrane is disposed between the second membrane and the reservoir, wherein at least a portion of the second membrane is spaced apart from the first membrane forming a vapor chamber between the first and second membranes.

Abstract: A capsule of a volatile substance distribution system is configured for use with a base unit having a fan and an air outlet configured to direct air driven by the fan away from the base unit. The capsule includes a housing that extends along a longitudinal axis between a first end and a second end. The first end defines an inlet port and the second end defines an outlet port. The housing houses a volatile substance member. The capsule further includes an outlet seal member that seals and unseals the outlet port. The housing, when engaged with the base unit and with the outlet seal member in the unsealed position, is configured to receive the air from the air outlet that flows into the inlet port, past the volatile substance member, and out of the outlet port.

Abstract: A compact diffuser integrates an atomizer and droplet separator into a surrounding sleeve, threadable to a bottle neck as an assembly. The assembly fits into a base, housing a motor and air pump, sealing the sleeve to a silo in the housing. Controls set time span of intermittent operation, intervening delay, and volumetric flow rate. The assembly pops into (and out of) the top end of a silo in the base, registering (aligning) circumferentially and axially to seal an air path from the pump to the atomizer. Access for applying force to the bottom of the assembly facilitates popping out the assembly when empty, or to simply change scent by changing out the assembly. Entire assemblies may be stored to simplify exchange and reduce chances for spills from reservoirs.

Abstract: A sterilizable lamp assembly of a vehicle may include at least one sterilizing lamp mounted in an indoor of a vehicle and for irradiating sterilizable light of wavelength to the interior of the vehicle, wherein the sterilizing lamp is configured to emit light when a passenger does not get on the interior of the vehicle.

Abstract: A system and method for an air purification assembly that creates high volume, sterilized straight-line airflow with a significant reduction in electricity consumption utilizing counter rotation of two propellers mounted in reverse to create linear airflow and thrust that sucks in air through an inlet and blows the air out through an outlet. Air purification assembly may also sterilize the air as it passes through light utilizing a light core system with a ring-shaped assembly that has one or more UV-C LEDs that may kill bio-organisms within proximity to the air purification assembly while dissipating the heat created by the UVC LED lights in the light core system.

Abstract: The invention relates to an insect trap (10) and more particularly to an insect trap which has been designed to facilitate the destruction of micro-organisms thereby countering odours and mitigating against the spread of germs. The trap (10) comprises a. a housing (12); b. a cover (14); c. one or a plurality of insect attracting lights (16); and d. an insect catching means (18) and further comprises a UVC lamp which emits radiation (or other means) which is capable of destroying air-borne pathogens. The insect attractant lamps (16) heat the air which is convected as a consequence of louvered openings (26) in the cover and an opening (30) in the top (28) of the trap and circulate across the UVC lamp where the micro-organisms are killed.

Abstract: A fibrous structure exhibits an absorbency time of equal to or less than 1.5 s and exhibits an antimicrobial effect.

Abstract: An adhesive composition described herein comprises an aqueous solvent; and a population of first nanoparticles dispersed in the aqueous solvent, the first nanoparticles comprising a negative or positive charge, and an average size in three dimensions of 1 nm to 1000 nm. In some embodiments, a population of second nanoparticles is dispersed in the aqueous solvent, the second nanoparticles comprises a negative or positive charge opposite the charge of the population of first nanoparticles. In some embodiments, the population of first nanoparticles comprise an average first size in three dimensions, and the population of second nanoparticles comprise an average second size in three dimensions that is different from the average first size of the first nanoparticles.

Abstract: The invention is directed to a biodegradable tissue-adhesive polyurethane polymer comprising at least one amorphous segment and at least one polyurethane segment, wherein at least one of said polyurethane segment comprises a tissue-reactive functional group. A further aspect of the invention is directed to biodegradable tissue-adhesive medical devices, based on the polyurethane polymer, having the structure of a sheet, foam, stent, tube or gel. The polyurethane polymer and the device can be used in medical application.

Abstract: A formulation, or tissular adhesive, obtained from a platelet-rich blood composition and/or growth factors, and method for the preparation of this adhesive. The preparation method of the adhesive comprises the steps of raising the temperature of the initial blood composition and subsequently activating the composition. Among other advantages, the tissular adhesive is biocompatible and biodegradable, has desirable biological or medical properties provided by the presence of platelets or growth factors, and also has a high adhesiveness and an accelerated coagulation process.

Abstract: A curable composition apportioned between at least one Part A and at least one Part B, the Parts sealed within barrier means preventing contamination, the at least one Part A comprising: (i) one or more alkenyl-group containing prepolymers having at least one alkenyl group or moiety per molecule, and the at least one Part B comprising: (ii) one or more SiH-containing prepolymers having at least one Si—H unit per molecule; the composition additionally comprising: (iii) a catalyst for curing by addition of alkenyl-containing prepolymer (i) to SiH-containing prepolymer (ii), wherein prepolymer (ii) is substantially absent from Part A and prepolymer (i) is substantially absent from Part B, methods for preparing the composition, methods for sterilisation thereof, medical and non-medical use thereof, a device incorporating the composition, and a precursor therefor including its sterilisable precursor composition, in particular a terminally sterilisable or terminally sterile composition for medical use, particularl

Abstract: A medical device at least partially formed of a metal alloy of duplex steel.

Abstract: The invention relates to a polyurethane bone-tendon graft biomaterial and method of making the bone-tendon graft biomaterial. The biomaterial has a gradient of mechanical properties through photocrosslinking such that a first end of the biomaterial is crosslinked at a higher degree than a second end, and the first end of the biomaterial has mechanical properties of bone and the second end of the biomaterial has mechanical properties of tendon.

Abstract: Injectable macroporous hydrogels, and methods of producing same, are described. The injectable macroporous hydrogels may be formed by mixing gelatin microgels with an enzyme. In at least some embodiments, the enzyme may be transglutaminase, and more specifically microbial transglutaminase (mTG).

Abstract: A composition and methods of making or use thereof include a plurality of fibers forming a shape for augmenting fixation of a bone screw, or the plurality of fibers form a shape having a peg portion and a sheet portion to augment tendon to bone repair. The physical presence of the plurality of fibers provides initial fixation, while the use of an osteoinductive material provides long term enhancement of bone formation around the site of the bone screw or the tendon to bone repair.

Abstract: A self-reinforcing composite gel includes a solvent, and a plurality of swellable crosslinked polymer particles dispersed in a crosslinked polymer matrix, wherein the crosslinked polymer matrix and the plurality of swellable crosslinked polymer particles are immersed in the solvent, wherein the swellable crosslinked polymer particles absorb more solvent at equilibrium than the matrix polymer, and wherein the plurality of swellable crosslinked polymer particles swell in the solvent and are present in an amount sufficient to maintain or increase the elastic modulus and/or load-bearing ability of the self-reinforcing composite gel, i.e., compared to that of the crosslinked matrix polymer alone, upon swelling in the solvent.

Abstract: A medical implant is disclosed. The medical implant includes: a first biocompatible metal forming a substrate (210, 310, 410), a second biocompatible metal diffused into the first biocompatible metal to form an biocompatible alloy surface (220, 314, 414), the alloy surface further including a diffusion hardening species, wherein the diffusion hardening species may be carbon, nitrogen, oxygen, boron, or any combination thereof. A method of forming a medical implant is also disclosed. The method includes the steps of: providing a first biocompatible metal or alloy that forms a substrate (210, 310, 410), providing a second biocompatible metal or alloy, diffusing the second biocompatible metal into the first biocompatible metal to form an alloy layer (220, 314, 414), removing excess second metal material from the substrate to expose the alloy layer, and diffusion hardening the alloy layer.

Abstract: The present invention relates to a biomaterial-derived sheet-like decellularized material having a maximum value of tensile strength in four directions of 4 MPa or more and an elongation rate in the direction exhibiting the maximum tensile strength of 50% to 300%. The present invention can provide a sheet-like material capable of maintaining excellent pressure resistance when used as an artificial blood vessel or for repair of a blood vessel.

Abstract: Methods and compositions for use in repairing and/or regenerating tissues are disclosed. A hydrogel precursor composition comprising functionalized tissue particles and functionalized hyaluronic acid that can be deposited into an implant site and converted into a crosslinked hydrogel network which retains the tissue particles at the implant site is disclosed. Also disclosed are methods of forming functionalized tissue particles and functionalized hyaluronic acid for use herein. Kits containing reagents for producing the hydrogel precursor composition are also disclosed, along with methods of producing the hydrogel precursor composition.

Abstract: Embodiments of the present invention provide a method for treatment of nonvascular body lumen strictures such as benign prostatic hyperplasia (BPH), urethral strictures, ureteral strictures, prostate cancer, esophageal strictures, sinus strictures, biliary tract strictures, asthma and chronic obstructive pulmonary disease (COPD). The method involves delivering, preferably via drug coated balloon catheters, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and one or more additives.

Abstract: Biomaterials and methods and uses for repair or augmentation of tissues are provided. In particular, the invention provides a multi-layered, naturally occurring multi-axial oriented biomaterial comprising predominately type I collagen fibers. The invention further provides methods and uses for repair or augmentation of tissues using biomaterials of the invention.

Abstract: An endoluminal device includes a composite yarn with a polymer yarn and an alloy wire. The polymer yarn includes a biodegradable polymer, and the alloy wire includes a biocompatible alloy. An endoluminal device can include a plurality of polymer yarns and at least one alloy wire, in which the polymer yarns include a biodegradable polymer, and the least one alloy wire includes a biocompatible alloy. A surgical system or kit includes an endoluminal device and a delivery instrument.

Abstract: A method for preparing a chitosan/heparinized graphene oxide composite multilayer film on the surface of a medical magnesium alloy comprises the following steps: firstly preparing negatively charged heparinized graphene oxide; then performing surface chemical treatment and self-assembly of 16-phosphonohexadecanoic acid molecules on the medical magnesium alloy; further covalently immobilizing chitosan on the surface of the magnesium alloy, thereby constructing a positively charged material surface; finally, alternately immersing the surface-modified magnesium alloy material in heparinized graphene oxide and a chitosan solution, and then fully adsorbing, and obtaining the chitosan/heparinized graphene oxide composite multilayer film after drying.

Abstract: The present invention relates to a coating system for medical devices comprising at least one cellulose compound or derivative thereof alone or in combination with other substances. The coating system may further comprise at least one active ingredient intended to treat a disease and the coating has favorable drug eluting properties. The present invention has applications in implantable or non-implantable medical devices such as balloons, stents, grafts, patches and implants of all kinds.

Abstract: Methods for applying a coating to a surface of a substrate for inhibition and prevention of implant-associated complications (including implant-associated infections), methods for inhibiting and preventing implant-associated complications (including implant-associated infections), implant-associated infection inhibiting coatings, and coated devices are provided. Coating processes include a) providing a saturated or supersaturated solution of an antibiotic in a fast-evaporating or medium-evaporating organic solvent; b) coating the surface of the substrate with at least one application of solution, each application followed directly by a solvent evaporation period.

Abstract: An autonomous medical waste collection assembly comprises a base adapted to be positioned near a patient. At least one wheel is powered to move the base along a floor surface. A waste collection unit is coupled to the base for receiving medical waste from the patient. The waste collection unit includes a canister for holding the medical waste. A controller is operable to initiate a waste disposal protocol. The waste disposal protocol includes transmitting a movement signal to the powered wheel for automatically moving the autonomous medical waste collection assembly away from the patient to a disposal station. A user input device is in communication with the controller. The user input device is adapted to provide a user input signal in response to being actuated by a user. The controller is configured to initiate the waste disposal protocol in response to receiving the user input signal.